SCHEMBL16446271

SCHEMBL16446271

CC(C)(CCCO)C(=O)CC#N

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.42
CYP4A11 Q02928 2/20 0.42
MCL1 Q07820 4/20 0.34
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22833607 0.88 MCL1 (0.37) MCL1
SCHEMBL14234360 0.81 CES2 (0.39) MCL1
SCHEMBL10349033 0.81 CES2 (0.39) MCL1
SCHEMBL22519796 0.79 MCL1 (0.41) MCL1TDP1
SCHEMBL769518 0.79 MCL1 (0.39) MCL1
SCHEMBL22502333 0.75
SCHEMBL4079532 0.74 MCL1 (0.41) MCL1
SCHEMBL330556 0.72 MCL1 (0.38) MCL1
SCHEMBL28031057 0.72 MCL1 (0.38) MCL1
SCHEMBL133731 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
WO-2023009712-A1 HETEROARYLOXY THIAZOLO AZINES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2023-02-02 WO disclosed
WO-2023009709-A1 PYRAZOLO PIPERAZINES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2023-02-02 WO disclosed
WO-2023009708-A1 HETEROARYLOXY TRIAZOLO- AND IMIDAZO-AZINES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2023-02-02 WO disclosed
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2022-12-29 US disclosed
WO-2022140527-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed
WO-2021226261-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2021-11-11 WO disclosed
US-9605004-B2 Chemical compounds SYNGENTA LIMITED (GB) 2017-03-28 US disclosed
US-20160168126-A1 CHEMICAL COMPOUNDS SYNGENTA LIMITED (GB) 2016-06-16 US disclosed
EP-3030080-A1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES Syngenta Participations AG (CH) 2016-06-15 EP disclosed
EP-3030082-A1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES Syngenta Participations AG (CH) 2016-06-15 EP disclosed
US-20160159819-A1 CHEMICAL COMPOUNDS SYNGENTA LIMITED (GB) 2016-06-09 US disclosed
US-20160159819-A1 CHEMICAL COMPOUNDS SYNGENTA LIMITED (GB) 2016-06-09 US disclosed
US-20160159819-A1 CHEMICAL COMPOUNDS SYNGENTA LIMITED (GB) 2016-06-09 US disclosed
WO-2015018433-A1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-02-12 WO disclosed
WO-2015018434-A1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-02-12 WO disclosed
WO-2015018433-A1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-02-12 WO disclosed
WO-2015018434-A1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168126-A1 CHEMICAL COMPOUNDS RDX, CBR3, RRS1 CYP4F2 426/4885CYP4A11 924/4885MCL1 2469/4885
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B CYP4F2 3371/4885CYP4A11 3504/4885MCL1 84/4885
US-20160159819-A1 CHEMICAL COMPOUNDS RDX, CBR3, RRS1 CYP4F2 261/4885CYP4A11 715/4885MCL1 2518/4885
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B CYP4F2 3371/4885CYP4A11 3504/4885MCL1 84/4885
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B CYP4F2 3371/4885CYP4A11 3504/4885MCL1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.